🔍

RELIGARE - Religare Enterp.

📊 NSE: RELIGARE 🏢 Finance & Investments 📅 Last Updated: 12/14/2025 11:48

📢 Recent Corporate Announcements

Religare Subsidiary Care Health Appoints Ajay Kumar Shah as MD & CEO for 5-Year Term

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 26 Apr 2026, 10:53 PM

Religare Enterprises has announced the appointment of Ajay Kumar Shah as the Managing Director & CEO of its material subsidiary, Care Health Insurance Limited (CHIL), effective April 26, 2026. Mr. Shah, who has been with CHIL for 14 years, succeeds the outgoing leadership as part of an internal succession plan. The appointment has already received necessary approval from the IRDAI for a five-year tenure. Given his history as Chief Business Officer where he oversaw a 30x growth in Gross Written Premium, the transition is expected to be stable.

Ajay Kumar Shah appointed as MD & CEO of Care Health Insurance for a 5-year term starting April 26, 2026
IRDAI has already granted approval for the appointment, ensuring regulatory compliance
Mr. Shah has over 30 years of experience and has spent 14 years at CHIL in various leadership roles
Under his leadership as Chief Business Officer, CHIL's Gross Written Premium (GWP) grew more than 30-fold over 10 years
The appointment follows an internal succession plan, suggesting continuity in business strategy

💡 Investors should take confidence in the internal succession and the appointee's strong track record of scaling the insurance business. No immediate action is required, but monitor the subsidiary's growth trajectory under the new leadership.

Religare Subsidiary Care Health Appoints Ajay Kumar Shah as MD & CEO for 5 Years

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 26 Apr 2026, 10:49 PM

Religare Enterprises has announced the appointment of Mr. Ajay Kumar Shah as the Managing Director & CEO of its material subsidiary, Care Health Insurance Limited (CHIL), for a five-year term starting April 26, 2026. Mr. Shah, a Chartered Accountant with over 30 years of experience, has been with CHIL for 14 years and currently serves as its Chief Business Officer. The appointment has already received approval from the IRDAI and follows an internal succession plan. Under his business leadership over the last decade, CHIL's Gross Written Premium (GWP) has grown more than 30 times.

Mr. Ajay Kumar Shah appointed as MD & CEO of Care Health Insurance for a 5-year term effective April 26, 2026.
IRDAI approval has been secured for the appointment, with shareholder approval pending.
Mr. Shah has 14 years of experience at CHIL and over 30 years in the insurance and financial services sectors.
CHIL's Gross Written Premium (GWP) grew over 30x during his tenure leading business verticals.
The appointment is part of an internal succession plan aimed at maintaining growth and operational stability.

💡 Investors should view this as a positive move for leadership continuity in Religare's most significant subsidiary. The appointment of an internal high-performer suggests a stable growth trajectory for Care Health Insurance.

Religare Appoints Ajay Kumar Shah as MD & CEO of Care Health Insurance for 5-Year Term

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 26 Apr 2026, 10:45 PM

Religare Enterprises has announced the appointment of Mr. Ajay Kumar Shah as the Managing Director and CEO of its material subsidiary, Care Health Insurance Limited (CHIL), effective April 26, 2026. Mr. Shah, who has been with CHIL for 14 years, previously served as the Chief Business Officer and has over 30 years of experience in the financial services sector. Under his leadership of business verticals over the last decade, CHIL's Gross Written Premium (GWP) has grown more than 30-fold. The appointment has already received approval from the IRDAI, ensuring a smooth leadership transition for this critical business unit.

Mr. Ajay Kumar Shah appointed as MD & CEO of Care Health Insurance for a 5-year term starting April 26, 2026.
CHIL's Gross Written Premium (GWP) grew over 30x during his 10-year tenure leading business verticals.
The appointment has received formal approval from the IRDAI and follows an internal succession plan.
Mr. Shah is a Chartered Accountant with over 30 years of experience in Insurance and Financial Services.

💡 Investors should view this as a positive development for business continuity and growth, given the appointee's significant role in CHIL's historical scaling. Monitor the subsidiary's performance as it remains a primary value driver for Religare Enterprises.

Religare Enterprises Reports Zero Demat Requests for Quarter Ended March 31, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 16 Apr 2026, 06:42 PM

Religare Enterprises Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that no requests for dematerialization of securities were received during the quarter ended March 31, 2026. Since no requests were received, the standard procedures for certificate cancellation and depository substitution were not applicable. This filing is a standard administrative requirement for listed companies in India.

Compliance certificate submitted for the quarter ended March 31, 2026.
Registrar KFin Technologies Limited confirmed zero dematerialization requests were received.
The filing confirms adherence to SEBI (Depositories and Participants) Regulations, 2018.
No security certificates required mutilation or cancellation during the reporting period.

💡 This is a routine administrative disclosure with no impact on the company's financial health or operations. No action is required from investors.

Religare to Hold EGM for Office Shift and Appointment of Executive Director with ₹9 Cr Salary

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 11 Apr 2026, 06:08 PM

Religare Enterprises has scheduled an Extraordinary General Meeting (EGM) on May 05, 2026, to seek shareholder approval for shifting its registered office from Delhi to Haryana. A key agenda item is the appointment of Mr. Arjun Lamba as Whole Time Director for a five-year term starting April 01, 2026. The proposed remuneration for Mr. Lamba includes a fixed salary of ₹9.00 crore per annum, with potential annual hikes of up to 25%. Additionally, he will be eligible for a variable bonus of up to 50% of his fixed pay and participation in the company's ESOP plan.

Extraordinary General Meeting (EGM) scheduled for May 05, 2026, via Video Conferencing.
Proposal to shift the Registered Office from the National Capital Territory of Delhi to the State of Haryana.
Appointment of Mr. Arjun Lamba as Whole Time Director (Executive Director) for a 5-year tenure until March 2031.
Proposed fixed remuneration for the new Executive Director set at ₹9.00 crore per annum.
Variable pay component capped at 50% of fixed pay, alongside eligibility for Employee Stock Option Plans (ESOPs).

💡 Investors should review the proposed executive remuneration package and the rationale for the office relocation during the EGM. Monitor the voting outcomes to gauge shareholder sentiment regarding the high-value management compensation.

Religare Enterprises to Hold Extra-Ordinary General Meeting (EGM) on May 05, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Apr 2026, 07:44 PM

Religare Enterprises Limited has announced an Extra-Ordinary General Meeting (EGM) scheduled for May 05, 2026, at 11:00 AM. The meeting will be conducted virtually via Video Conferencing or Other Audio Visual Means in compliance with MCA and SEBI guidelines. The company will distribute the EGM notice electronically to shareholders whose email addresses are registered with the company or its RTA. This is a procedural announcement ahead of the actual meeting where specific corporate resolutions will be discussed.

EGM scheduled for May 05, 2026, at 11:00 AM IST.
Meeting to be held via Video Conferencing (VC) / Other Audio Visual Means (OAVM).
Notice of EGM will be sent only in electronic mode to registered members.
Shareholders can update email addresses via KFin Technologies Limited (RTA).

💡 Investors should ensure their email IDs are updated with the RTA to receive the full EGM notice. Once the notice is available, review the specific agenda items to understand any proposed corporate actions.

Religare Enterprises Grants 22,692 Stock Options at Rs. 220.34 Exercise Price

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Mar 2026, 10:04 PM

Religare Enterprises Limited (REL) has granted 22,692 stock options to eligible employees under its Employee Stock Option Plan 2019. Each option is convertible into one equity share of face value Rs. 10 at a fixed exercise price of Rs. 220.34. The vesting schedule is spread over five years, with 20% of the options vesting annually starting one year from the grant date. This routine corporate action is designed to retain talent and align employee interests with long-term company performance.

Grant of 22,692 stock options under the REL Employee Stock Option Plan 2019.
Exercise price set at Rs. 220.34 per equity share.
Vesting occurs in 5 equal annual installments of 20% each starting March 2027.
Options can be exercised within 8 years from the date of vesting.
Each option is convertible into one equity share of face value Rs. 10.

💡 No action is required as the quantity of options granted is negligible compared to the total equity base and will not cause significant dilution. Investors should continue to monitor the company's overall management stability and growth trajectory.

Religare Subsidiary Care Health Gets Stay from Bombay HC on ₹35.36 Cr GST Demand & Penalty

🟢 POSITIVE ⭐ 7/10

LEGAL 📅 30 Mar 2026, 07:00 PM

Religare Enterprises' material subsidiary, Care Health Insurance Limited (CHIL), has obtained a stay order from the Bombay High Court against a GST demand order. The original demand included ₹17.68 crore in GST and an equivalent penalty of ₹17.68 crore, totaling approximately ₹35.36 crore excluding interest. The dispute pertains to SEZ-related matters for the period FY 2017-18 to FY 2023-24. The stay provides temporary financial relief as the company contests what it describes as an industry-wide tax issue.

Bombay High Court granted a stay on the GST order-in-original until final disposal of the writ petition.
The total financial implication involves a tax demand of ₹17.68 crore and a penalty of ₹17.68 crore.
The tax dispute covers a seven-year period from July 2017 to March 2024 regarding SEZ matters.
Religare identifies the tax demand as part of an industry-wide issue rather than a company-specific lapse.

💡 Investors should monitor the final outcome of the writ petition as the stay is temporary, though it prevents immediate cash outflow. The resolution of this 'industry-wide' issue will be a significant indicator for the subsidiary's long-term tax liabilities.

Religare Appoints Arjun Lamba as Executive Director for 5 Years; New Chairperson Named

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 30 Mar 2026, 06:01 PM

Religare Enterprises has announced a significant leadership transition, appointing Mr. Arjun Lamba as Whole Time Director (Executive Director) for a five-year term effective April 1, 2026. Mr. Lamba, who has over 23 years of experience in capital markets, was notably involved in the Burman family's acquisition efforts for Religare and Eveready. Additionally, Mr. Rajender Mohan Malla will serve as the Non-Executive Chairperson for a short interim period from April 1 to June 30, 2026. These appointments are subject to shareholder approval and signal a potential shift in strategic direction under the influence of major stakeholders.

Mr. Arjun Lamba appointed as Whole Time Director for a 5-year term starting April 1, 2026
Mr. Rajender Mohan Malla appointed as Non-Executive Chairperson for a 3-month tenure ending June 30, 2026
Mr. Lamba brings 23+ years of experience and is the founder of Guardian Advisors, a SEBI-registered PMS
Appointment is significant as Mr. Lamba played a key role in the Burman family's acquisition of Religare Enterprises
The leadership changes are subject to the approval of the company's shareholders

💡 Investors should monitor how this leadership change affects the ongoing corporate governance dynamics and the potential takeover bid by the Burman family. The short-term appointment of the Chairperson suggests further board restructuring may be expected by mid-2026.

Religare Enterprises Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Mar 2026, 02:39 PM

Religare Enterprises Limited has informed the stock exchanges that its trading window for dealing in company shares will be closed starting April 01, 2026. This action is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the financial results for the quarter and year ending March 31, 2026. The window will remain closed until 48 hours after the financial results are declared. The specific date for the Board Meeting to approve these results will be announced at a later date.

Trading window closure begins on April 01, 2026.
Closure is related to the financial results for the quarter and year ending March 31, 2026.
Trading restriction ends 48 hours after the official declaration of financial results.
The announcement is a mandatory compliance under SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory filing and does not impact the company's fundamentals. Investors should monitor for the upcoming announcement of the Board Meeting date to review the Q4 and FY26 financial performance.

Religare Subsidiary Care Health Insurance Receives Rs 140.20 Cr Income Tax Demand

🔴 NEGATIVE ⭐ 7/10

LEGAL 📅 18 Mar 2026, 10:58 PM

Religare Enterprises' material subsidiary, Care Health Insurance Limited (CHIL), has received income tax demand orders totaling Rs 140.20 crore for the assessment years 2023-24 and 2024-25. The demand arises from disallowances related to claim provisions (IBNR/IBNER) and marketing expenses, which the company claims are industry-wide issues. CHIL expects to reduce the demand to approximately Rs 96 crore through a rectification application and intends to appeal the orders. The company notes that similar issues have been adjudicated in its favor by judicial forums in previous years.

Cumulative income tax demand of Rs 140.20 crore (including interest) issued against Care Health Insurance Limited.
Demand pertains to Assessment Years 2023-24 and 2024-25 regarding disallowances of claim provisions and marketing expenses.
Company estimates the demand will be rectified down to approximately Rs 96 crore post-correction of computation errors.
CHIL plans to file an appeal, citing that IBNR/IBNER issues were previously settled in their favor by the Delhi High Court.
The tax demand, if finalized, will impact the consolidated financials of Religare Enterprises Limited.

💡 Investors should monitor the outcome of the rectification and appeal process as the demand represents a significant contingent liability. While the company has a history of favorable rulings on these specific issues, the immediate demand may create short-term pressure on the stock.

Religare Enterprises Q3 FY26 Income Rises to ₹2,067.9 Cr; Care Health AUM Crosses ₹10,000 Cr

🔵 WATCH ⭐ 8/10

EARNINGS 📅 20 Feb 2026, 11:07 PM

Religare Enterprises reported a consolidated total income of ₹2,067.9 crores for Q3 FY26, up from ₹1,670.2 crores in the same quarter last year. Despite revenue growth, the company posted a consolidated loss before tax of ₹103.1 crores, impacted by one-time employee benefit provisions under the new labor code. The insurance subsidiary, Care Health, remains a strong performer with retail business growing 41% and its AUM crossing the ₹10,000 crore milestone. Governance remains a focal point with the proposed induction of Burman family members and Jimeet Modi to the Board.

Consolidated total income increased to ₹2,067.9 crores in Q3 FY26 vs ₹1,670.2 crores in Q3 FY25.
Care Health Insurance retail premium grew by 41% YoY, with total 9M premium reaching ₹7,906 crores.
Care Health AUM crossed ₹10,000 crores with a solvency ratio of 1.70 as of December 2025.
One-time wage code provisions of ₹13.5 crores impacted quarterly profitability in the insurance segment.
Board expansion proposed to include Dr. Anand Burman, Mohit Burman, Aditya Chand Burman, and Jimeet Modi.

💡 Investors should monitor the transition in board leadership and the impact of the new management team on long-term strategy. While the consolidated loss is a concern, the robust growth and market share gains in the health insurance subsidiary provide a strong underlying valuation support.

Religare Enterprises Reports Q3 FY26 Net Loss of ₹76.5 Cr; Care Health GWP Grows to ₹7,906 Cr

🔵 WATCH ⭐ 8/10

EARNINGS 📅 15 Feb 2026, 11:57 PM

Religare Enterprises Limited (REL) reported a consolidated net loss of ₹76.5 crore for Q3 FY26, compared to a loss of ₹63.2 crore in the same period last year. While total income grew by 23.8% YoY to ₹2,067.9 crore, rising expenses and higher claims in the insurance segment weighed on profitability. Care Health Insurance remains the primary growth engine, contributing ₹7,906 crore in GWP for 9M FY26 with a 22% market share in the SAHI segment. The company's NBFC arm, Religare Finvest, is now debt-free with over ₹500 crore in cash reserves following successful NPA recoveries.

Consolidated Total Income increased 23.8% YoY to ₹2,067.9 crore in Q3 FY26.
Care Health Insurance GWP grew to ₹7,906 crore for 9M FY26, up from ₹6,508 crore YoY.
Consolidated Net Loss for 9M FY26 stood at ₹22.5 crore versus a profit of ₹32 crore in 9M FY25.
Care Health's AUM crossed a significant milestone, reaching ₹10,246 crore as of December 2025.
Religare Finvest (NBFC) has resolved legacy issues and maintains a cash balance of ₹500+ crore.

💡 Investors should focus on the improving operational metrics of Care Health and the debt-free status of the NBFC arm, while remaining cautious about the widening consolidated losses. Monitor the combined ratio in the insurance business, which rose to 111.1% in Q3 FY26, as a key indicator of future profitability.

Religare Enterprises Announces Strategic Demerger of Financial Services; 1:1 Share Swap Ratio

🟢 POSITIVE ⭐ 9/10

M&A 📅 14 Feb 2026, 08:52 PM

Religare Enterprises (REL) has approved a demerger to separate its financial services and insurance businesses into two independent listed entities. The financial services business, including lending and broking, will be transferred to Religare Finvest Limited (RFL), while REL will retain the insurance business through Care Health Insurance. Shareholders will receive 1 share of RFL for every 1 share held in REL. The demerged undertaking contributed ₹457.29 crore (6.2%) to the consolidated turnover in FY25.

Demerger of lending, broking, and investment activities into Religare Finvest Limited (RFL)
Shareholders to receive 1 fully paid-up equity share of RFL for every 1 share held in REL
Demerged business accounted for ₹457.29 crore (6.2%) of FY25 consolidated turnover
REL to remain an insurance-focused entity holding the stake in Care Health Insurance Limited
RFL to be listed on BSE and NSE with a target completion date in Q1 FY28

💡 Investors should maintain their positions to benefit from the value unlocking of two distinct business platforms. Monitor the progress of regulatory approvals from the RBI and NCLT, as these are critical for the Q1 FY28 listing timeline.

Religare Enterprises Announces 1:1 Demerger of Financial Services Business into Religare Finvest

🟢 POSITIVE ⭐ 9/10

M&A 📅 14 Feb 2026, 08:50 PM

Religare Enterprises (REL) has approved a scheme to demerge its financial services, broking, and investment businesses into its subsidiary, Religare Finvest Limited (RFL). Shareholders will receive one equity share of RFL for every one share held in REL, with RFL set to be listed on both BSE and NSE. The demerged undertaking contributed INR 457.29 Crores, or 6.2% of the total consolidated turnover, in FY25. Post-demerger, REL will focus on its insurance business through Care Health Insurance, while RFL will operate as an independent lending and broking entity.

Shareholders to receive 1 share of Religare Finvest for every 1 share held in Religare Enterprises.
Demerged financial services division reported a turnover of INR 457.29 Crores (6.2% of total) in FY25.
Religare Enterprises will retain its core investment and shareholding in Care Health Insurance Limited.
Religare Finvest (RFL) is expected to be listed on BSE and NSE by Q1 FY28.
The scheme involves a 100% mirror-image shareholding pattern for the new listed entity.

💡 Investors should maintain their positions to benefit from the value unlocking of two distinct listed entities. However, note the long implementation timeline with listing expected only by Q1 FY28.

View All RELIGARE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Care Health Insurance GWP grew 18.6% to INR 5,104 Cr in H1 FY26; Religare Broking revenue declined 18.9% to INR 89.6 Cr in Q2 FY26; Religare Housing revenue declined 12.1% to INR 7.41 Cr in Q2 FY26; Consolidated Total Income grew 5.67% to INR 2,082.7 Cr in Q2 FY26.

Geographic Revenue Split

Religare Broking revenue split: West (30%), North (29%), South (24%), and East (17%). E-Governance revenue split: East (34%), North (32%), West (17%), and South (17%).

Profitability Margins

Consolidated PAT margin for Q2 FY26 was 2.2% (INR 45.9 Cr PAT on INR 2,082.7 Cr income). Care Health PBT (N basis) grew 113% to INR 177 Cr in H1 FY26. Religare Broking PBT margin fell to 3.68% in Q2 FY26 from 16.2% YoY.

EBITDA Margin

Consolidated PBT margin was 2.76% in Q2 FY26, down from 3.42% in Q2 FY25, primarily due to higher 'Other Expenses' which rose 16.1% to INR 1,403 Cr.

Capital Expenditure

Concluded a preferential issue of INR 1,500 Cr in Sept 2025; infused INR 322 Cr into Care Health Insurance in Sept 2025 to support business growth and maintain a solvency ratio of 1.89.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company's cost of borrowing is noted as high, and it recently transitioned to a debt-free status for its RFL subsidiary.

⚙️ Operational Drivers

Raw Materials

Not applicable for financial services; primary cost drivers are Insurance Claims (68.1% ratio) and Finance Costs (INR 9.8 Cr in Q2 FY26).

Capacity Expansion

Care Health Investment Book grew by INR 900 Cr to INR 9,500 Cr as of Sept 2025; Religare Broking AUC stands at INR 43,000 Cr.

Raw Material Costs

Claims Ratio for Care Health normalized at 68.1% in H1 FY26 compared to 65.1% YoY; Finance costs decreased 24% to INR 9.8 Cr in Q2 FY26.

Manufacturing Efficiency

Not applicable; however, collection efficiency for RFL is maintained at 98% in the standard book.

Logistics & Distribution

Distribution costs (Fee and Commission) for the consolidated entity were INR 367.2 Cr in Q2 FY26, representing 17.6% of total income.

📈 Strategic Growth

Expected Growth Rate

18.60%

Growth Strategy

Achieving growth through a technology refresh to increase digital acquisition, re-entering the MSME lending market via RFL post-RBI CAP removal, and utilizing the INR 1,500 Cr capital infusion to scale operations across all financial service verticals.

Products & Services

health insurance policies, MSME loans, housing loans, demat accounts, e-governance services (bus/train/flight booking)

Brand Portfolio

Religare, Care Health Insurance

New Products/Services

Expanding wealth offerings in broking and increasing revenue share from E-Governance services through a network of agents.

Market Expansion

Re-entering the credit ecosystem post-RBI CAP removal in July 2025 to expand MSME credit reach.

Market Share & Ranking

Care Health holds a 9.9% market share in the overall health insurance space and 19.2% among Standalone Health Insurers (SAHI).

Strategic Alliances

Burman Group designated as promoters post-open offer; preferential issue included participation from marquee investors (INR 750 Cr).

🌍 External Factors

Industry Trends

Health insurance is outpacing general industry growth, with Care Health's GWP growing 18.6% YoY; India's demat penetration remains low at ~7-10% compared to 65% in the US, providing a long-term growth runway.

Competitive Landscape

Intense competition in the group insurance segment from General Insurance (GI) and SAHI players; broking segment faces competition from discount brokers.

Competitive Moat

Multi-channel distribution network where the Agency segment contributes 40% of insurance business; strong retail focus (62% of insurance book) provides granular revenue and reduces corporate client dependency.

Macro Economic Sensitivity

Demand for health insurance and broking services is highly sensitive to India's financial literacy rates and demat penetration (currently ~7-10%).

Consumer Behavior

Shift toward digital acquisition and app-based trading; increasing demand for retail health insurance post-COVID.

Geopolitical Risks

Minimal direct impact due to domestic focus, though global market volatility affects AUC and broking volumes.

⚖️ Regulatory & Governance

Industry Regulations

IRDAI accounting change to 1/N basis for long-term policies; RBI Corrective Action Plan (CAP) on RFL (removed July 2025); Expense of Management (EOM) regulations (compliant at 32.2%).

Taxation Policy Impact

Consolidated tax expense was INR 11.5 Cr in Q2 FY26; RHDFCL tax expense was INR 0.7 Cr.

Legal Contingencies

Delhi High Court order removed the 'fraud' tag on Religare Finvest Limited (RFL), facilitating its re-entry into the credit market.

⚠️ Risk Analysis

Key Uncertainties

Regulatory accounting changes (1/N) impacting reported profitability by INR 154 Cr in H1 FY26; competitive pricing pressure in group insurance segments.